Similar articles

• Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.

  Langer F, Chun FK, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, Bokemeyer C, Francis JL. Langer F, et al. Thromb Haemost. 2007 Mar;97(3):464-70. Thromb Haemost. 2007. PMID: 17334515
• [Cancer procoagulant--biochemical characteristics and the influence on the development of neoplastic disease].

  Kamocka M, Mielicki WP. Kamocka M, et al. Postepy Biochem. 2003;49(3):168-74. Postepy Biochem. 2003. PMID: 15083609 Review. Polish. No abstract available.
• Acute lymphoblastic leukemia (ALL) and cancer procoagulant activity.

  Pogliani EM, Lanzafame C, Bucciarelli P, Corneo G. Pogliani EM, et al. Haematologica. 1991 Nov-Dec;76(6):526-7. Haematologica. 1991. PMID: 1688361 No abstract available.
• The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.

  Kehinde EO, Maghrebi MA, Anim JT. Kehinde EO, et al. Can J Urol. 2008 Apr;15(2):3967-74. Can J Urol. 2008. PMID: 18405443 Review.
• New circulating biomarkers for prostate cancer.

  Bensalah K, Lotan Y, Karam JA, Shariat SF. Bensalah K, et al. Prostate Cancer Prostatic Dis. 2008;11(2):112-20. doi: 10.1038/sj.pcan.4501026. Epub 2007 Nov 13. Prostate Cancer Prostatic Dis. 2008. PMID: 17998918 Review.